Start Your Search
OA03 - Systemic Therapies for SCLC: Novel Targets and Patients' Selection (ID 121)
- Event: WCLC 2019
- Type: Oral Session
- Track: Small Cell Lung Cancer/NET
- Presentations: 1
- Now Available
- Moderators:Christine Lee Hann, Makoto Nishio
- Coordinates: 9/08/2019, 13:30 - 15:00, Hilton Head (1978)
OA03.01 - A Non-Randomized, Open-Label, Prospective, Multicenter Study of Apatinib as Second-Line and Later-Line Therapy in Patients with ES-SCLC (Now Available) (ID 486)
13:30 - 15:00 | Author(s): Jun Hua
Small-cell lung cancer (SCLC) accounts for approximately 10–15% of the total number of lung cancer cases. In extensive-stage (ES) SCLC, the 5-year survival rate is less than 5%, which was mainly caused by rapid recurrence and resistance to second-line chemotherapy despite the high response to first-line chemotherapy. This study evaluated the efficacy and safety of apatinib, an orally administered small-molecule targeted drug, in second-line and later-line therapy for patients with ES-SCLC (ChiCTR-OPC-17013964）.Method
From July 28, 2017 to March 24, 2019, 52 patients who failed in first-line and above chemotherapy treatment were enrolled and received apatinib 500 mg per day. The efficacy was evaluated after 4-weeks treatment (1 cycle), and then evaluated once every 2 cycles. The primary endpoint was progression-free survival (PFS), and secondary endpoints were overall survival (OS), overall response rate (ORR) and disease control rate (DCR). The adverse events were also recorded.Result
Of 52 enrolled patients, 36 patients were available for efficacy analysis. The median PFS was 6.18 months (95%CI: 3.26-7.99) and the median OS did not achieve. The mPFS of patients received apatinib as second-line treatment was 6.48 months. Patients who received first-line chemotherapy more than 6 months had longer PFS and OS than patients received less than 6months. 31 patients were available for tumor response evaluation. The ORR and DCR were 19.35% and 83.87%, respectively. During the treatment, 96 adverse events were detected. Among them, 3-4 grade adverse reactions were hypertension (8.33%), hand-foot syndrome (5.56%), hypodynamia (5.56%) and proteinuria (2.78%), which all alleviated by reducing dose and symptomatic treatment.
Table 1 Patient baseline characteristics
Apatinib was effective for SCLC patients who failed in first-line and above chemotherapy and the adverse events were tolerable.
Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.